News

The Osteosarcoma Institute to Fund Clinical Trial in Recurrent Osteosarcoma at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

The clinical trial will investigate the effectiveness of a combination of two oral drugs targeting the DNA damage response pathway.

Dana-Farber/Boston Children’s faculty named 2020 Top Doctors

Boston magazine has named at least 25 faculty members of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center to its annual "Top Doctors" guide.

Dana-Farber/Boston Children's nation’s #1 pediatric cancer program

U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.

Children with cancer wait an average of 6.5 years longer than adults to access new targeted drugs, finds study at Dana-Farber/Boston Children’s

Researchers call for expanding children’s access to experimental cancer therapies

Team led by Dana-Farber/Boston Children’s Kimberly Stegmaier receives SU2C Sharp Award from Stand Up To Cancer

Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.

Researchers at Dana-Farber/Boston Children's and UMass Medical School optimize gene editing for sickle cell disease and beta thalassemia

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.

Dana-Farber/Boston Children's Brian D. Crompton, MD, awarded research grant by the Go4theGoal Foundation

The Go4theGoal Foundation (G4TG) recently awarded Brian Crompton, MD, of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a $50,000 research grant.

Fishing for new leads in rare mucosal melanoma

Vector reports that zebrafish are helping scientists dissect intricate molecular pathways in cancer and discover new treatment approaches.

Dana-Farber and Boston Children’s Hospital teams win Moonshot grants

The federal Beau Biden Cancer Moonshot program has awarded two grants of $2.5 million over five years to two research teams led by scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

In zebrafish, a way to find new cancer therapies, targeting tumor promoters

Vector reports on a new study that finds that retinoic acid, best known as an acne treatment, may also be effective in treating adenoid cystic carcinoma.